Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Infinity Pharmaceuticals, a small-molecule drug firm in Cambridge, Mass., will obtain development and commercialization rights to Intellikine’s portfolio of inhibitors of the δ and γ isoforms of phosphoinositide-3-kinase (PI3K). They include INK1197, a cancer therapy that is expected to enter the clinic next year. Under the license agreement, Intellikine will receive $13.5 million in initial payments, development payments of up to $25 million, and commercialization payments of up to $450 million.
This article has been sent to the following recipient: